A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook
2019 Total Revenue Grew 31% to $120.4 Million ; Genomic Test Volume Grew 25% to 39,612 Achieved Fourth Quarter 2019 Positive Cash Flow from Operations Fourth Quarter Acquisition Positions Company for Global Expansion Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Veracyte to Present at the 9th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 13, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27,
View HTML
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2019 Financial Results on February 25, 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the fourth quarter and full-year 2019 after the close of market on Tuesday, February 25, 2020 .
View HTML
Toggle Summary Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma
Agreement enabled by Veracyte acquisition of NanoString diagnostics assets for global expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Veracyte (Nasdaq: VCYT) today announced a multi-year partnership with Acerta Pharma, the hematology research and development arm of
View HTML
Toggle Summary Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally
Strategic transaction enables Veracyte to access global markets through a world-class, distributed instrument system, with an initial focus on its pulmonology franchise Provides pathway for long-term revenue growth and margin expansion Veracyte to hold conference call and webcast today at 5:30 p.m.
View HTML
Toggle Summary Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer
Findings Presented at 89 th Annual Meeting of the American Thyroid Association SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data that advance understanding of the frequency, positive predictive value and co-occurrence of genomic
View HTML
Toggle Summary Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association
Findings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data advancing the understanding of
View HTML
Toggle Summary Veracyte Announces Third Quarter 2019 Financial Results and Business Progress
Revenue Grew 32% to $31.0 Million Genomic Test Volume Grew 24% to 9,941 Company Presents Preliminary Data for First-Ever Noninvasive Nasal Swab Test for Lung Cancer Early Detection Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct.
View HTML
Toggle Summary Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis
Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021 Conference call and webcast today at 5:00 p.m. ET to review third quarter 2019 Financial results and the new nasal swab test data SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Oct.
View HTML
Toggle Summary Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive
Data Being Presented at CHEST Annual Meeting 2019 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 21, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced data demonstrating the clinical validity of its next-generation Percepta ® Genomic Sequencing Classifier (GSC) and the clinical utility of
View HTML